Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash & Equivalents: 2011-2024

Historic Cash & Equivalents for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to $11.3 million.

  • Capricor Therapeutics' Cash & Equivalents fell 71.47% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year decrease of 71.47%. This contributed to the annual value of $11.3 million for FY2024, which is 23.19% down from last year.
  • As of FY2024, Capricor Therapeutics' Cash & Equivalents stood at $11.3 million, which was down 23.19% from $14.7 million recorded in FY2023.
  • In the past 5 years, Capricor Therapeutics' Cash & Equivalents ranged from a high of $34.9 million in FY2021 and a low of $9.6 million during FY2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $11.3 million (2024), whereas its average is $11.9 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 738.61% in 2020, then slumped by 72.47% in 2022.
  • Over the past 5 years, Capricor Therapeutics' Cash & Equivalents (Yearly) stood at $32.7 million in 2020, then rose by 6.68% to $34.9 million in 2021, then tumbled by 72.47% to $9.6 million in 2022, then skyrocketed by 53.02% to $14.7 million in 2023, then decreased by 23.19% to $11.3 million in 2024.